Literature DB >> 8656226

A computer-assisted telephone interview technique for assessment of asthma morbidity and drug use in adult asthma.

K A Anie1, P W Jones, S R Hilton, H R Anderson.   

Abstract

This study concerns an analysis of the feasibility, validity, and repeatability of telephone interviews for the collection of data concerning health-related quality of life in asthma and patient reports of their use of asthma therapy. A computer-assisted hierarchical interview algorithm was developed that allowed rapid and precise recording of all aspects of asthma medication including drug, dose, and delivery system. This questionnaire was used together with the Symptoms and Impacts components of the St. George's Respiratory Questionnaire (SGRQ) in one face-to-face and then in three computer-assisted telephone interviews (CATIs) that took place 1, 3, and 13 weeks later. One hundred patients with asthma who had received inhaled steroids within the previous year were identified from general practice records. The intraclass correlation between the face-to-face interview and the first CATI for the SGRQ scores and the daily dose of inhaled steroid was approximately 0.8. For daily bronchodilator use, this value was 0.56. The intraclass correlation obtained between two CATIs 3 months apart was a little lower: SGRQ scores, 0.78; inhaled steroid dose, 0.67; bronchodilator use, 0.58. Telephone interviews can provide repeatable and efficient measurements of health and patient-reported drug use in asthma.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8656226     DOI: 10.1016/0895-4356(95)00583-8

Source DB:  PubMed          Journal:  J Clin Epidemiol        ISSN: 0895-4356            Impact factor:   6.437


  9 in total

1.  Using the standard error of measurement to identify important changes on the Asthma Quality of Life Questionnaire.

Authors:  Kathleen W Wyrwich; William M Tierney; Fredric D Wolinsky
Journal:  Qual Life Res       Date:  2002-02       Impact factor: 4.147

Review 2.  Patient self-reports in pharmacoeconomic studies. Their use and impact on study validity.

Authors:  C Evans; B Crawford
Journal:  Pharmacoeconomics       Date:  1999-03       Impact factor: 4.981

Review 3.  Interfacing computers and the internet with your allergy practice.

Authors:  Jonathan A Bernstein
Journal:  Clin Rev Allergy Immunol       Date:  2004-10       Impact factor: 8.667

4.  Self-management of asthma in general practice, asthma control and quality of life: a randomised controlled trial.

Authors:  B P A Thoonen; T R J Schermer; G Van Den Boom; J Molema; H Folgering; R P Akkermans; R Grol; C Van Weel; C P Van Schayck
Journal:  Thorax       Date:  2003-01       Impact factor: 9.139

5.  Survey on appropriateness of use of nimesulide in nine European countries.

Authors:  Silvia Franchi; Franca Heiman; Elena Visentin; Paola Sacerdote
Journal:  Drug Healthc Patient Saf       Date:  2015-03-16

6.  Comparative impact of two continuing education activities targeted at COPD educators on educational outcomes: protocol for a non-randomized controlled study using mixed methods.

Authors:  Myriam Gagné; Jocelyne Moisan; Sophie Lauzier; Christine Hamel; Patricia Côté; Jean Bourbeau; Louis-Philippe Boulet
Journal:  BMC Health Serv Res       Date:  2018-06-18       Impact factor: 2.655

7.  Analysis of two questionnaires on quality of life of Chronic Obstructive Pulmonary Disease patients.

Authors:  Ana Folch Ayora; Loreto Macia Soler; Agueda Cervera Gasch
Journal:  Rev Lat Am Enfermagem       Date:  2019-07-18

Review 8.  Towards dealing with commonly occurring requirements engineering process issues during software development outsourcing.

Authors:  Javed Iqbal; Rodina B Ahmad; Fazal-E- Amin; Muhammad Shoaib; Mohd Hairul Nizam Nasir
Journal:  PLoS One       Date:  2022-07-14       Impact factor: 3.752

9.  Using patient reported outcome measures in health services: a qualitative study on including people with low literacy skills and learning disabilities.

Authors:  Deepa Jahagirdar; Thilo Kroll; Karen Ritchie; Sally Wyke
Journal:  BMC Health Serv Res       Date:  2012-11-26       Impact factor: 2.655

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.